A P. falciparum Merozoite Surface Protein-1 Malaria Vaccine Produced in Transgenic Plants

Category: Biology and Medicine

Reference Number: 00313

Description

This technology describes a method of producing transgenic tobacco plants that synthesize the complete P. falciparum MSP1 p42 polypeptide. This structure of the plant MSP1 p42 recombinant polypeptide appears to be similar to that obtained from P. falciparum as well as from the baculovirus expression system.

Applications

Malaria vaccine

Main Advantages

Production of a malaria vaccine by transgenic plants would reduce raw material costs and make the vaccine more affordable for distribution to developing countries. In addition, it would also abrogate the risk of potential contamination of the vaccine with animal pathogens.

Inventor(s)

Sandra Chang, Benjamin Vine
Tropical Medicine & Medical Microbiology

Wei-Wen Su, Robert Bugos
Molecular Biosciences & Biosystems Engineering

Contact Information

For licensing information, please contact Lisa Matsunaga at matsunag@hawaii.edu

For all other inquiries, please write to:

Office of Technology Transfer & Economic Development
University of Hawai’i
2800 Woodlawn Drive, Suite 280
Honolulu, HI 96822